|
|
Article: Axonyx Starting Phase III Study Of Phenserine For Alzheimer's.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
National Editor
Hoping to back up the positive data yielded from a Phase II trial, Axonyx Inc. began a Phase III trial in Europe of its Alzheimer's disease drug Phenserine, an acetylcholinesterase and beta-amyloid peptide inhibitor.
"This is pretty exciting," said Matt Kaplan, analyst with Punk, Ziegel & Co. in New York. "It's a new drug that could have an impact on disease progression."
Several existing acetylcholinesterase inhibitors address the symptoms and can improve short-term memory, but do not slow the disease, he added.
The randomized, placebo-controlled, double-blind trial will evaluate the safety and efficacy of two ...